A France-based vaccine developer focused on infectious diseases, with a portfolio that includes approved vaccines for Japanese encephalitis and cholera as well as late‑stage candidates targeting Lyme disease and chikungunya. The company operates primarily through research, development, and commercia...
No congressional trades have been disclosed for Valneva SE (VALN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.